Patents by Inventor Brian Cajes

Brian Cajes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
    Publication number: 20260193651
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing an oligonucleotide that targets MTRES1 in a subject.
    Type: Application
    Filed: November 30, 2023
    Publication date: July 9, 2026
    Inventors: Omri GOTTESMAN, Emma BRANDT, Shannon BRUSE, Paul BUSKE, Eric BUSS, Brian CAJES, David JAKUBOSKY, David LEWIS, Gregory MCINNES, David ROZEMA, John VEKICH, Darren H. WAKEFIELD
  • Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
    Patent number: 12674165
    Abstract: Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: July 7, 2026
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
    Publication number: 20260176623
    Abstract: Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs) for therapeutic use, additionally, methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
    Type: Application
    Filed: February 7, 2025
    Publication date: June 25, 2026
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
    Publication number: 20260091053
    Abstract: Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (lfTSLP).
    Type: Application
    Filed: May 19, 2025
    Publication date: April 2, 2026
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
    Publication number: 20260055410
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
    Type: Application
    Filed: March 12, 2025
    Publication date: February 26, 2026
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
  • TREATMENT OF MS4A4E RELATED DISEASES AND DISORDERS
    Publication number: 20250368990
    Abstract: Disclosed herein are MS4A4E inhibitors such as oligonucleotides that target MS4A4E. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MS4A4E mutations that include providing an MS4A4E inhibitor to a subject.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 4, 2025
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Eric BUSS, Brian CAJES, David JAKUBOSKY, Gregory MCINNES, John VEKICH, David ROZEMA
  • TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS
    Publication number: 20250333732
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.
    Type: Application
    Filed: May 23, 2023
    Publication date: October 30, 2025
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David JAKUBOSKY, Gregory MCINNES, David ROZEMA, John VEKICH
  • SMALL MOLECULE TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
    Publication number: 20250327127
    Abstract: Disclosed herein are compositions comprising a small molecule that targets MTRES1. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a small molecule that targets MTRES1 in a subject.
    Type: Application
    Filed: October 23, 2023
    Publication date: October 23, 2025
    Inventors: Omri GOTTESMAN, Emma BRANDT, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, David LEWIS, Gregory MCINNES, David ROZEMA, John VEKICH
  • TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
    Publication number: 20250313841
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.
    Type: Application
    Filed: April 3, 2025
    Publication date: October 9, 2025
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
  • Treatment of angiopoietin like 7 (ANGPTL7) related diseases
    Patent number: 12378556
    Abstract: Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: August 5, 2025
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Paul Buske, Brian Cajes, David Lewis, David Rozema
  • Process to Inhibit or Eliminate Eosinophilic Diseases of the Airway and Related Conditions
    Publication number: 20250228883
    Abstract: Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs), antisense oligonucleotides, and small molecule inhibitors for therapeutic use. Additionally provided are methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
    Type: Application
    Filed: August 29, 2024
    Publication date: July 17, 2025
    Inventors: Shannon BRUSE, Brian CAJES, Omri GOTTESMAN, David ROZEMA, David LEWIS
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES
    Publication number: 20250197859
    Abstract: Provided herein are compositions comprising an oligonucleotide that targets ANGPTL7. In some embodiments, the oligonucleotide includes modified nucleotides. In some embodiments, the oligonucleotide may be used to reduce intraocular pressure in a subject's eye.
    Type: Application
    Filed: March 27, 2023
    Publication date: June 19, 2025
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David LEWIS, David ROZEMA
  • TREATMENT OF HGFAC RELATED DISEASES AND DISORDERS
    Publication number: 20250195555
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets HGFAC. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating cancer that include providing an oligonucleotide that targets HGFAC in a subject.
    Type: Application
    Filed: March 16, 2023
    Publication date: June 19, 2025
    Inventors: Omri GOTTESMAN, Andrew ALLEN, Shannon BRUSE, Brian CAJES, David JAKUBOSKY, David LEWIS, Gregory MCINNES, Jason O'ROURKE, David ROZEMA, Paul BUSKE
  • Treatment of MST1 related diseases and disorders
    Patent number: 12312586
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.
    Type: Grant
    Filed: August 7, 2024
    Date of Patent: May 27, 2025
    Assignee: Empirico Inc.
    Inventors: Omri Gottesman, Shannon Bruse, Paul Buske, Brian Cajes, David Jakubosky, Sarah Kleinstein, David Lewis, David Rozema, John Vekich
  • PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20250090559
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Application
    Filed: November 26, 2024
    Publication date: March 20, 2025
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA
  • TREATMENT OF FGG RELATED DISEASES AND DISORDERS
    Publication number: 20250043281
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.
    Type: Application
    Filed: December 5, 2022
    Publication date: February 6, 2025
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David LEWIS, David ROZEMA, John VEKICH
  • TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
    Publication number: 20240392295
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MS1. The oligonucleotide may include a small interfering RNA (siRNA) or art antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
    Type: Application
    Filed: August 5, 2024
    Publication date: November 28, 2024
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
  • TREATMENT OF MST1 RELATED DISEASES AND DISORDERS
    Publication number: 20240392296
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.
    Type: Application
    Filed: August 7, 2024
    Publication date: November 28, 2024
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
  • TREATMENT OF MST1R RELATED DISEASES AND DISORDERS
    Publication number: 20240392299
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MST1R. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1R mutations that include providing an oligonucleotide that targets MST1R to a subject.
    Type: Application
    Filed: June 14, 2022
    Publication date: November 28, 2024
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH
  • TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
    Publication number: 20240287518
    Abstract: Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing an oligonucleotide that targets MTRES1 in a subject.
    Type: Application
    Filed: June 14, 2022
    Publication date: August 29, 2024
    Inventors: Omri GOTTESMAN, Shannon BRUSE, Paul BUSKE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, David LEWIS, David ROZEMA, John VEKICH